Over the next five years, QBC Diagnostics will grow rapidly to a number one position in underserved physician's office lab hematology markets by achieving waived status in the United States.  Our fluorescence microscopy product line will continue to build a formidable presence with malaria and tuberculosis diagnostics and will expand into analytical, research, and additional infectious disease markets.  We will accomplish this through strong relationships with our business partners; focused research and development, product development, and marketing teams, along with strong support from our global training, distribution, and service partners.  We will stay customer centric with a focus on creating innovative solutions for a healthier world in both developing and developed countries.